SU11248A1
(en)
|
1927-03-29 |
1929-09-30 |
В.С. Григорьев |
Anthracene cleaning method
|
CU22545A1
(en)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
|
US4289872A
(en)
|
1979-04-06 |
1981-09-15 |
Allied Corporation |
Macromolecular highly branched homogeneous compound based on lysine units
|
JPS57206622A
(en)
|
1981-06-10 |
1982-12-18 |
Ajinomoto Co Inc |
Blood substitute
|
US4671958A
(en)
|
1982-03-09 |
1987-06-09 |
Cytogen Corporation |
Antibody conjugates for the delivery of compounds to target sites
|
US4486414A
(en)
|
1983-03-21 |
1984-12-04 |
Arizona Board Of Reagents |
Dolastatins A and B cell growth inhibitory substances
|
US4753894A
(en)
|
1984-02-08 |
1988-06-28 |
Cetus Corporation |
Monoclonal anti-human breast cancer antibodies
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
US4625014A
(en)
|
1984-07-10 |
1986-11-25 |
Dana-Farber Cancer Institute, Inc. |
Cell-delivery agent
|
US4542225A
(en)
|
1984-08-29 |
1985-09-17 |
Dana-Farber Cancer Institute, Inc. |
Acid-cleavable compound
|
GB8430252D0
(en)
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
WO1987000056A1
(en)
|
1985-06-26 |
1987-01-15 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5229490A
(en)
|
1987-05-06 |
1993-07-20 |
The Rockefeller University |
Multiple antigen peptide system
|
US4816444A
(en)
|
1987-07-10 |
1989-03-28 |
Arizona Board Of Regents, Arizona State University |
Cell growth inhibitory substance
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
US4847325A
(en)
|
1988-01-20 |
1989-07-11 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
GB8824591D0
(en)
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Fractionation process
|
US5076973A
(en)
|
1988-10-24 |
1991-12-31 |
Arizona Board Of Regents |
Synthesis of dolastatin 3
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
DE68925966T2
(en)
|
1988-12-22 |
1996-08-29 |
Kirin Amgen Inc |
CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US4978744A
(en)
|
1989-01-27 |
1990-12-18 |
Arizona Board Of Regents |
Synthesis of dolastatin 10
|
JP2875884B2
(en)
|
1989-04-19 |
1999-03-31 |
ノボ ノルディスク アクティーゼルスカブ |
Active polyalkylene oxide carbonates for use in modifying polypeptides
|
US5122614A
(en)
|
1989-04-19 |
1992-06-16 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
US5324844A
(en)
|
1989-04-19 |
1994-06-28 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
US4879278A
(en)
|
1989-05-16 |
1989-11-07 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
|
US4986988A
(en)
|
1989-05-18 |
1991-01-22 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
|
ATE136315T1
(en)
|
1989-05-27 |
1996-04-15 |
Sumitomo Pharma |
METHOD FOR THE PRODUCTION OF POLYETHYLENE GLYCOL DERIVATIVES AND MODIFIED PROTEINS.
|
US5138036A
(en)
|
1989-11-13 |
1992-08-11 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
|
US5312808A
(en)
|
1989-11-22 |
1994-05-17 |
Enzon, Inc. |
Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
|
US5219564A
(en)
|
1990-07-06 |
1993-06-15 |
Enzon, Inc. |
Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
|
EP0513332A4
(en)
|
1990-11-14 |
1993-03-17 |
Cargill, Incorporated |
Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
|
US5252714A
(en)
|
1990-11-28 |
1993-10-12 |
The University Of Alabama In Huntsville |
Preparation and use of polyethylene glycol propionaldehyde
|
ATE247168T1
(en)
|
1991-03-06 |
2003-08-15 |
Merck Patent Gmbh |
HUMANIZED MONOCLONAL ANTIBODIES
|
JPH06506217A
(en)
|
1991-03-18 |
1994-07-14 |
エンゾン,インコーポレーテッド |
Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5281698A
(en)
|
1991-07-23 |
1994-01-25 |
Cetus Oncology Corporation |
Preparation of an activated polymer ester for protein conjugation
|
IT1260468B
(en)
|
1992-01-29 |
1996-04-09 |
|
METHOD FOR MAINTAINING THE ACTIVITY OF PROTEOLYTIC ENZYMES MODIFIED WITH POLYETHYLENGLYCOL
|
CA2118130A1
(en)
|
1992-04-14 |
1993-10-28 |
Jean M. J. Frechet |
Dendritic based macromolecules and method of production
|
ZA933926B
(en)
|
1992-06-17 |
1994-01-03 |
Amgen Inc |
Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
|
WO1994004193A1
(en)
|
1992-08-21 |
1994-03-03 |
Enzon, Inc. |
Novel attachment of polyalkylene oxides to bio-effecting substances
|
US5382657A
(en)
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US6034065A
(en)
|
1992-12-03 |
2000-03-07 |
Arizona Board Of Regents |
Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
NZ250375A
(en)
|
1992-12-09 |
1995-07-26 |
Ortho Pharma Corp |
Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
|
US5298643A
(en)
|
1992-12-22 |
1994-03-29 |
Enzon, Inc. |
Aryl imidate activated polyalkylene oxides
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
WO1994015625A1
(en)
|
1993-01-15 |
1994-07-21 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
US5349001A
(en)
|
1993-01-19 |
1994-09-20 |
Enzon, Inc. |
Cyclic imide thione activated polyalkylene oxides
|
US5410024A
(en)
|
1993-01-21 |
1995-04-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US5321095A
(en)
|
1993-02-02 |
1994-06-14 |
Enzon, Inc. |
Azlactone activated polyalkylene oxides
|
IL104734A0
(en)
|
1993-02-15 |
1993-06-10 |
Univ Bar Ilan |
Bioactive conjugates of cellulose with amino compounds
|
AU7097094A
(en)
|
1993-06-01 |
1994-12-20 |
Enzon, Inc. |
Carbohydrate-modified polymer conjugates with erythropoietic activity
|
AU7113594A
(en)
|
1993-06-21 |
1995-01-17 |
Enzon, Inc. |
Site specific synthesis of conjugated peptides
|
GB9317618D0
(en)
|
1993-08-24 |
1993-10-06 |
Royal Free Hosp School Med |
Polymer modifications
|
US5919455A
(en)
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5711944A
(en)
|
1993-11-10 |
1998-01-27 |
Enzon, Inc. |
Interferon polymer conjugates
|
US5951974A
(en)
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
US5446090A
(en)
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
GB9401182D0
(en)
|
1994-01-21 |
1994-03-16 |
Inst Of Cancer The Research |
Antibodies to EGF receptor and their antitumour effect
|
US5473034A
(en)
|
1994-03-18 |
1995-12-05 |
Hyogo Prefectural Government |
Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
|
US5629384A
(en)
|
1994-05-17 |
1997-05-13 |
Consiglio Nazionale Delle Ricerche |
Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
|
WO1995033490A1
(en)
|
1994-06-02 |
1995-12-14 |
Enzon, Inc. |
Method of solubilizing substantially water insoluble materials
|
US5730990A
(en)
|
1994-06-24 |
1998-03-24 |
Enzon, Inc. |
Non-antigenic amine derived polymers and polymer conjugates
|
US5521284A
(en)
|
1994-08-01 |
1996-05-28 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides and esters
|
US5504191A
(en)
|
1994-08-01 |
1996-04-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide methyl esters
|
US5530097A
(en)
|
1994-08-01 |
1996-06-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory peptide amides
|
WO1996004925A1
(en)
|
1994-08-12 |
1996-02-22 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
US5650234A
(en)
|
1994-09-09 |
1997-07-22 |
Surface Engineering Technologies, Division Of Innerdyne, Inc. |
Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
|
US5554725A
(en)
|
1994-09-14 |
1996-09-10 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Synthesis of dolastatin 15
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
EP0804584B2
(en)
|
1994-10-21 |
2008-07-09 |
Innogenetics N.V. |
Sequences of hepatitis c virus genotype 7 and their use as prophylactic, therapeutic and diagnostic agents
|
WO1996041813A2
(en)
|
1994-11-09 |
1996-12-27 |
Offord Robin E |
Functionalized polymers for site-specific attachment
|
US5738846A
(en)
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US5599902A
(en)
|
1994-11-10 |
1997-02-04 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Cancer inhibitory peptides
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5932462A
(en)
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
US5756662A
(en)
|
1995-03-14 |
1998-05-26 |
Corixa Corporation |
Compounds and methods for the detection of T. cruzi infection
|
PT821671E
(en)
|
1995-04-20 |
2001-04-30 |
Pfizer |
ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS
|
JPH11507535A
(en)
|
1995-06-07 |
1999-07-06 |
イムクローン システムズ インコーポレイテッド |
Antibodies and antibody fragments that suppress tumor growth
|
WO1996040791A1
(en)
|
1995-06-07 |
1996-12-19 |
Novo Nordisk A/S |
Modification of polypeptides
|
US5672662A
(en)
|
1995-07-07 |
1997-09-30 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
DE69624081T2
(en)
|
1995-12-20 |
2003-06-12 |
Hoffmann La Roche |
Matrix metalloprotease inhibitors
|
TR199801532T2
(en)
|
1996-02-09 |
1998-11-23 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFalpha.
|
HUP9901155A3
(en)
|
1996-02-13 |
2003-04-28 |
Astrazeneca Ab |
Quinazoline derivatives as vegf inhibitors
|
PT885198E
(en)
|
1996-03-05 |
2002-06-28 |
Astrazeneca Ab |
4-ANYLINOQUINAZOLINE DERIVATIVES
|
US5747639A
(en)
|
1996-03-06 |
1998-05-05 |
Amgen Boulder Inc. |
Use of hydrophobic interaction chromatography to purify polyethylene glycols
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
WO1998003516A1
(en)
|
1996-07-18 |
1998-01-29 |
Pfizer Inc. |
Phosphinate based inhibitors of matrix metalloproteases
|
CA2262994A1
(en)
|
1996-08-02 |
1998-02-12 |
Ortho-Mcneil Pharmaceutical, Inc. |
Polypeptides having a single covalently bound n-terminal water-soluble polymer
|
US5980948A
(en)
|
1996-08-16 |
1999-11-09 |
Osteotech, Inc. |
Polyetherester copolymers as drug delivery matrices
|
IL128189A0
(en)
|
1996-08-23 |
1999-11-30 |
Pfizer |
Arylsulfonylamino hydroxamic acid derivatives
|
US6130237A
(en)
|
1996-09-12 |
2000-10-10 |
Cancer Research Campaign Technology Limited |
Condensed N-aclyindoles as antitumor agents
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
EP0950059B1
(en)
|
1997-01-06 |
2004-08-04 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
JP2001508783A
(en)
|
1997-01-29 |
2001-07-03 |
ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー |
PEGylation method
|
ES2202796T3
(en)
|
1997-02-03 |
2004-04-01 |
Pfizer Products Inc. |
DERIVATIVES OF ARILSULFONYLAMINOHYDROXAMIC ACIDS.
|
EP0966438A1
(en)
|
1997-02-07 |
1999-12-29 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
JP3710489B2
(en)
|
1997-02-11 |
2005-10-26 |
ファイザー・インク |
Arylsulfonylhydroxamic acid derivatives
|
NZ337750A
(en)
|
1997-02-12 |
2001-08-31 |
Univ Michigan |
Protein markers for lung cancer and use thereof
|
WO1998036765A1
(en)
|
1997-02-25 |
1998-08-27 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
|
JP2002505574A
(en)
|
1997-04-30 |
2002-02-19 |
エンゾン,インコーポレイテッド |
Polyalkylene oxide-modified single-chain polypeptides
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US5990237A
(en)
|
1997-05-21 |
1999-11-23 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
|
AU744085B2
(en)
|
1997-06-06 |
2002-02-14 |
Kyowa Hakko Kirin Co., Ltd. |
Chemically modified polypeptides
|
IL133974A0
(en)
|
1997-07-14 |
2001-04-30 |
Bolder Biotechnology Inc |
Derivatives of growth hormone and related proteins
|
UA61963C2
(en)
|
1997-08-08 |
2003-12-15 |
Pfizer Prod Inc |
Aryloxysulfonylaminohydroxamic acid derivatives
|
JP2001517686A
(en)
|
1997-09-26 |
2001-10-09 |
ユーエイビー リサーチ ファンデーション |
Blood cells with reduced antigenicity and uses thereof
|
US6201072B1
(en)
|
1997-10-03 |
2001-03-13 |
Macromed, Inc. |
Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
|
US6004573A
(en)
|
1997-10-03 |
1999-12-21 |
Macromed, Inc. |
Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
|
DE19748489A1
(en)
|
1997-11-03 |
1999-05-06 |
Roche Diagnostics Gmbh |
Polyethylene glycol-derivatized biomolecules and their use in heterogeneous detection methods
|
US6448369B1
(en)
|
1997-11-06 |
2002-09-10 |
Shearwater Corporation |
Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
US5985263A
(en)
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US5981709A
(en)
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
JP4078032B2
(en)
|
1998-03-12 |
2008-04-23 |
ネクター セラピューティックス エイエル,コーポレイション |
Poly (ethylene glycol) derivatives with proximal reactive groups
|
JP4462654B2
(en)
|
1998-03-26 |
2010-05-12 |
ソニー株式会社 |
Video material selection device and video material selection method
|
PA8469501A1
(en)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
|
PA8469401A1
(en)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
BICYCLE DERIVATIVES OF HYDROXAMIC ACID
|
AU764144B2
(en)
|
1998-08-28 |
2003-08-14 |
Gryphon Therapeutics, Inc. |
Polyamide chains of precise length, methods to manufacture them and their conjugates
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6114361A
(en)
|
1998-11-05 |
2000-09-05 |
Pfizer Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
WO2000034337A1
(en)
|
1998-12-10 |
2000-06-15 |
Tsukuba Research Laboratory, Toagosei Co., Ltd. |
Humanized monoclonal antibodies against vascular endothelial cell growth factor
|
US6451346B1
(en)
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
JP4805432B2
(en)
|
1998-12-28 |
2011-11-02 |
ランクセス・ドイチュランド・ゲーエムベーハー |
Chemicals for admixing adhesives used in manufacturing wood materials or wood composite materials
|
CZ306810B6
(en)
|
1999-02-10 |
2017-07-19 |
Astrazeneca Ab |
The use of a quinazoline derivative as an inhibitor of angiogenesis
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
DE60026983T2
(en)
|
1999-04-16 |
2007-01-25 |
William Marsh Rice University, Houston |
FUNCTIONALIZED POLYPROPYLENE FUMARATE AND POLYPROPYLENE FUMARATE COETHYLENE GLYCOL
|
US6924359B1
(en)
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
US6323315B1
(en)
|
1999-09-10 |
2001-11-27 |
Basf Aktiengesellschaft |
Dolastatin peptides
|
NZ518028A
(en)
|
1999-11-05 |
2004-03-26 |
Astrazeneca Ab |
Quinazoline derivatives as VEGF inhibitors
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
PT1259563E
(en)
|
1999-12-22 |
2009-04-14 |
Nektar Therapeutics Al Corp |
Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.
|
WO2001046291A1
(en)
|
1999-12-22 |
2001-06-28 |
Shearwater Corporation |
Sterically hindered derivatives of water soluble polymers
|
US6413507B1
(en)
|
1999-12-23 |
2002-07-02 |
Shearwater Corporation |
Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
|
US6646110B2
(en)
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
ES2290117T3
(en)
|
2000-02-15 |
2008-02-16 |
Sugen, Inc. |
PROTEIN QUINASE 2-INDOLIN INHIBITORS REPLACED WITH PIRROL.
|
AU2001238595A1
(en)
|
2000-02-22 |
2001-09-03 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
ATE419354T1
(en)
|
2000-02-25 |
2009-01-15 |
Us Gov Health & Human Serv |
SCFV MOLECULES AGAINST EGFRVIII WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREOF, AND METHODS OF USE THEREOF
|
AU2001257577A1
(en)
|
2000-02-28 |
2001-09-03 |
Shearwater Corporation |
Water-soluble polymer conjugates of artelinic acid
|
KR100480985B1
(en)
|
2000-05-19 |
2005-04-07 |
이수화학 주식회사 |
Humanized antibodies to the epidermal growth factor receptor
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
TW593427B
(en)
|
2000-12-18 |
2004-06-21 |
Nektar Therapeutics Al Corp |
Synthesis of high molecular weight non-peptidic polymer derivatives
|
TWI246524B
(en)
|
2001-01-19 |
2006-01-01 |
Shearwater Corp |
Multi-arm block copolymers as drug delivery vehicles
|
US7045337B2
(en)
|
2001-04-19 |
2006-05-16 |
The Scripps Research Institute |
In vivo incorporation of unnatural amino acids
|
US20030083263A1
(en)
|
2001-04-30 |
2003-05-01 |
Svetlana Doronina |
Pentapeptide compounds and uses related thereto
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
HUP0600225A3
(en)
|
2001-06-13 |
2010-01-28 |
Genmab As |
Human monoclonal antibodies to epidermal growth factor receptor (egfr)
|
US6908963B2
(en)
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
MXPA04004336A
(en)
|
2001-11-07 |
2005-05-16 |
Nektar Therapeutics Al Corp |
Branched polymers and their conjugates.
|
WO2003039486A2
(en)
|
2001-11-09 |
2003-05-15 |
Idec Pharmaceuticals Corporation |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
DE10156482A1
(en)
|
2001-11-12 |
2003-05-28 |
Gundram Jung |
Bispecific antibody molecule
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
PT1545613E
(en)
|
2002-07-31 |
2011-09-27 |
Seattle Genetics Inc |
Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
EP1539948B1
(en)
|
2002-08-19 |
2009-10-14 |
The Board of Trustees of The Leland Stanford Junior University |
Improved methods of in vitro protein synthesis
|
BRPI0411475A
(en)
|
2003-06-18 |
2006-07-25 |
Scripps Research Inst |
unnatural reactive amino acid genetic code additions
|
BR122018071808B8
(en)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugate
|
US7968684B2
(en)
|
2003-11-12 |
2011-06-28 |
Abbott Laboratories |
IL-18 binding proteins
|
PT1682583E
(en)
|
2003-11-13 |
2012-04-13 |
Hanmi Holdings Co Ltd |
Protein complex using immunoglobulin fragment and method for the preparation thereof
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
US7976841B2
(en)
|
2004-04-30 |
2011-07-12 |
Institut National De La Sante Et De La Recherche |
Anti TfR antibody
|
KR101699142B1
(en)
|
2004-06-18 |
2017-01-23 |
암브룩스, 인코포레이티드 |
Novel antigen-binding polypeptides and their uses
|
JP5135504B2
(en)
|
2004-10-27 |
2013-02-06 |
ザ スクリプス リサーチ インスティチュート |
Orthogonal translation components for in vivo incorporation of unnatural amino acids
|
EP1828224B1
(en)
|
2004-12-22 |
2016-04-06 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
KR100754667B1
(en)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
|
CA2606102C
(en)
|
2005-04-26 |
2014-09-30 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
CA2624189A1
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
SG170116A1
(en)
|
2005-12-14 |
2011-04-29 |
Ambrx Inc |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
JP2009523815A
(en)
|
2006-01-19 |
2009-06-25 |
アンブルックス,インコーポレイテッド |
Unnatural amino acid polypeptides with regulated immunogenicity
|
EA018301B1
(en)
|
2006-04-21 |
2013-07-30 |
Новартис Аг |
Pharmaceutical compositions comprising antagonist monoclonal anti-cd40 antibody and use thereof
|
CN101479379B
(en)
|
2006-06-29 |
2012-01-18 |
利兰·斯坦福青年大学托管委员会 |
Cell-free synthesis of proteins containing unnatural amino acids
|
WO2008030612A2
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Site specific incorporation of non-natural amino acids by vertebrate cells
|
CN106008699A
(en)
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
Modified human plasma polypeptide or Fc scaffolds and their uses
|
WO2008083346A1
(en)
|
2006-12-28 |
2008-07-10 |
Ambrx, Inc. |
Phenazine and quinoxaline substituted amino acids and polypeptides
|
EP2155177A2
(en)
*
|
2007-04-30 |
2010-02-24 |
Intezyne Technologies Incorporated |
Modification of biological targeting groups for the treatment of cancer
|
MX2010003718A
(en)
|
2007-10-19 |
2010-04-21 |
Genentech Inc |
Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates.
|
WO2010051056A2
(en)
|
2008-03-11 |
2010-05-06 |
Ambrx, Inc. |
ANTI-FcεRI POLYPEPTIDES AND THEIR USES
|
JP5681102B2
(en)
*
|
2008-05-30 |
2015-03-04 |
シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッドSiemens Medical Solutions USA,Inc. |
Compounds for molecular imaging techniques
|
WO2010085682A2
(en)
|
2009-01-23 |
2010-07-29 |
Biogen Idec Ma Inc. |
Stabilized fc polypeptides with reduced effector function and methods of use
|
GB2470770A
(en)
|
2009-06-04 |
2010-12-08 |
Medical Res Council |
Incorporation of unnatural amino acids having an orthogonal functional group into polypeptides using orthogonal tRNA/tRNA synthetase pairs
|
WO2011044255A1
(en)
*
|
2009-10-06 |
2011-04-14 |
The Ohio State University |
Pyrrolysine analogs
|
JP6173911B2
(en)
|
2010-09-10 |
2017-08-09 |
メディミューン リミテド |
Antibody derivatives
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
CA2875989A1
(en)
|
2012-06-08 |
2013-12-12 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
HUE045227T2
(en)
*
|
2012-08-31 |
2019-12-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|